サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1159342

サイクリン依存性キナーゼ（CDK）阻害剤の世界市場（2022年～2028年）

Cyclin Dependent Kinase (CDK) Inhibitors Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 125 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
サイクリン依存性キナーゼ（CDK）阻害剤の世界市場（2022年～2028年）
出版日: 2022年10月17日
発行: Orion Market Research
ページ情報: 英文 125 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のサイクリン依存性キナーゼ（CDK）阻害剤の市場規模は、予測期間中にかなりのCAGRで成長すると予測されています。当市場を牽引する主な要因には、世界のがんの有病率の上昇などがあります。

当レポートでは、世界のサイクリン依存性キナーゼ（CDK）阻害剤市場を調査し、市場の概要、市場の促進要因・抑制要因の分析、市場機会、セグメント別、地域別の市場分析、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • Beta Pharma, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • Eli Lilly and Co.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • FLX Bio Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • G1 Therapeutics Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • Jiangsu Hengrui Medicine Co. Ltd.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • 主要戦略分析
  • COVID-19が主要企業に与える影響

第4章 市場セグメンテーション

  • タイプ別
    • 特定阻害剤
    • 非特異的阻害剤（広域阻害剤）
    • 複数標的阻害剤
  • 投与別
    • 鼻
    • 経口
    • 静脈内
    • 筋肉内
  • 用途別
    • 乳がん
    • リンパ腫
    • 多発性骨髄腫
    • 卵巣がん
    • その他（嚢胞性線維症）

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Novartis Pharma AG
  • Onconova Therapeutics, Inc.
  • Pfizer Inc.
  • Teijin Ltd.
  • ViroStatics srl
  • Xuanzhu Biopharmaceutical Co., Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL NON-SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL MULTIPLE TARGET CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
  • 6. GLOBAL NASAL FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL ORAL FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL INTRAVENOUS FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL INTRAMUSCULAR FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 11. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR BREAST CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OVARIAN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 19. NORTH AMERICAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 21. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 23. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
  • 24. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 25. ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 27. ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 29. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 31. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET, 2022-2028 (%)
  • 4. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL NON-SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL MULTIPLE TARGET CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY ADMINISTRATION, 2021 VS 2028 (%)
  • 9. GLOBAL NASAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL ORAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL INTRAVENOUS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL INTRAMUSCULAR CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 14. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR BREAST CANCER DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR LYMPHOMA DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR MULTIPLE MYELOMA DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 17. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OVARIAN CANCER DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OTHERS DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 19. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 20. US CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. CANADA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. UK CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. FRANCE CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. GERMANY CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. ITALY CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SPAIN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF EUROPE CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. INDIA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. CHINA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. JAPAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. SOUTH KOREA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026465

Global Cyclin Dependent Kinase (CDK) Inhibitors Market Size, Share & Trends Analysis Report by Type (Specific Inhibitors, Non-Specific Inhibitors, and Multiple Target Inhibitors), by Administration (Nasal, Oral, Intravenous, and Intramuscular), and by Application (Breast Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, And Others) Forecast Period 2022-2028

The global cyclin dependent kinase (CDK) inhibitors market is anticipated to grow at a substantial CAGR during the forecast period. One of the major factors driving the CDK inhibitors market is the rising prevalence of cancer across the globe. According to the World Health Organization (WHO), globally around 10 million deaths were reported which were caused due to cancer in 2020. In addition, the presence of a robust clinical pipeline due to the high demand for novel drugs and therapies is another factor propelling the growth of the market. Thus, market players are inclined toward launching novel CDK inhibitors to cater to the rising demand. For instance, in August 2020, ARC Therapeutic developed CDK inhibitors for treating advanced and resistant cancers. Currently, three CDK4/6 inhibitors including drugs such as Palbociclib, ribociclib, and abemaciclib have been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer by USFDA.

The global cyclin dependent kinase (CDK) inhibitors market is segmented based on the type, administration, and application. Based on the type, the market is segmented into specific inhibitors, non-specific or broad-range inhibitors, and multiple target inhibitors. Based on the administration, the market is sub-segmented into the nasal, oral, intravenous, and intramuscular. Based on application, the market is sub-segmented into breast cancer, lymphoma, multiple myeloma, ovarian cancer, and others. Among the administration segment, the oral sub-segment is expected to hold a considerable market share of the CDK inhibitors market over the forecast period, owing to the rising various R&D activities. For instance, in October 2021, the USFDA approved Verzenio in combination with endocrine therapy. Verzenio had been developed by Eli Lilly and Co. for treating HR+ HER2- early breast cancer. It is a non-chemotherapy oral tablet.

Geographically the global cyclin dependent kinase (CDK) inhibitors market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Among all the regions, North America is expected to hold a prominent share of the CDK inhibitors market during the forecast period, followed by Europe. The primary factor contributing to the regional growth includes the rising prevalence of cancer in the countries such as the US and Canada. According to the Canadian Cancer Society, in 2021, approximately 46% of the total Canadian population were diagnosed with cancer. Lung, breast, prostate, colorectal cancers are expected to remain the most commonly diagnosed cancer.

The major companies serving the global cyclin dependent kinase (CDK) inhibitors market include Beta Pharma, Inc., Eli Lilly & Co., FLX Bio, Inc., G1 Therapeutics Inc., Novartis Pharma AG, and Pfizer Inc., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, PilmoSIM Therapeutics strategically collaborated with investigators from National Jewish Health and Brown University for the clinical development of PT001. To provide curative treatment, this drug targets multiple responsible pathways in PAH.

Research Methodology

The market study of the global cyclin dependent kinase (CDK) inhibitors market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Cyclin Dependent Kinase (CDK) Inhibitors Market Research and Analysis by Type.

2. Global Cyclin Dependent Kinase (CDK) Inhibitors Market Research and Analysis by Administration.

3. Global Cyclin Dependent Kinase (CDK) Inhibitors Market Research and Analysis by Application.

The Report Covers:

  • Comprehensive Research Methodology of the global cyclin dependent kinase (CDK) inhibitors market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global cyclin dependent kinase (CDK) inhibitors market.
  • Insights about market determinants that are stimulating the global cyclin dependent kinase (CDK) inhibitors market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Cyclin Dependent Kinase (CDK) Inhibitors Market
  • Recovery Scenario of Global Cyclin Dependent Kinase (CDK) Inhibitors Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Beta Pharma, Inc.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Eli Lilly and Co.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. FLX Bio Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. G1 Therapeutics Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Jiangsu Hengrui Medicine Co. Ltd.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Type
    • 4.1.1. Specific Inhibitors
    • 4.1.2. Non-Specific Inhibitors (Broad Range Inhibitors)
    • 4.1.3. Multiple Target Inhibitors
  • 4.2. Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Administration
    • 4.2.1. Nasal
    • 4.2.2. Oral
    • 4.2.3. Intravenous
    • 4.2.4. Intramuscular
  • 4.3. Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Application
    • 4.3.1. Breast Cancer
    • 4.3.2. Lymphoma
    • 4.3.3. Multiple Myeloma
    • 4.3.4. Ovarian Cancer
    • 4.3.5. Others (Cystic Fibrosis)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Novartis Pharma AG
  • 6.2. Onconova Therapeutics, Inc.
  • 6.3. Pfizer Inc.
  • 6.4. Teijin Ltd.
  • 6.5. ViroStatics srl
  • 6.6. Xuanzhu Biopharmaceutical Co., Ltd.